An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer

A Phase 1/2a Study of BMS-986242 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1) in Advanced Malignant Tumors

The purpose of this study is to investigate safety of experimental medication BMS-986242 and Nivolumab in patients with advanced cancers.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Histologic or cytological confirmation of a malignancy that is advanced (metastatic and/or unresectable) with measureable disease per RECIST v1.1
• Participants must have received and then progressed or been intolerant to at least 1 standard treatment regimen in the advanced or metastatic setting if such a therapy exists
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
• Ability to swallow tablets
• Adequate bone marrow and organ function, as defined by the protocol

Exclusion Criteria:

• Participants with known or suspected CNS metastases, untreated CNS metastases, or with the CNS as the only site of disease (patients with controlled brain metastasis allowed to enroll)
• Ocular melanoma
• Any significant acute or chronic medical illness
• Prior malignancy
• Other active malignancy requiring concurrent intervention
• Prior organ allograft or allogeneic bone marrow transplantation
• Participants with active, known, or suspected autoimmune disease
• Requirement for daily supplemental oxygen
• Uncontrolled or significant cardiovascular disease
• Pre-existing liver disease
• Gastrointestinal disease known to interfere with absorption

Other protocol defined inclusion/exclusion criteria could apply